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Abstract
Background: In humans, serotonin has typically been investigated as a neurotransmitter.
However, serotonin also functions as a hormone across animal phyla, including those lacking an
organized central nervous system. This hormonal action allows serotonin to have physiological
consequences in systems outside the central nervous system. Fluctuations in estrogen levels over
the lifespan and during ovarian cycles cause predictable changes in serotonin systems in female
mammals.
Discussion: We hypothesize that some of the physiological effects attributed to estrogen may be
a consequence of estrogen-related changes in serotonin efficacy and receptor distribution. Here,
we integrate data from endocrinology, molecular biology, neuroscience, and epidemiology to
propose that serotonin may mediate the effects of estrogen. In the central nervous system,
estrogen influences pain transmission, headache, dizziness, nausea, and depression, all of which are
known to be a consequence of serotonergic signaling. Outside of the central nervous system,
estrogen produces changes in bone density, vascular function, and immune cell self-recognition and
activation that are consistent with serotonin's effects. For breast cancer risk, our hypothesis
predicts heretofore unexplained observations of the opposing effects of obesity pre- and post-
menopause and the increase following treatment with hormone replacement therapy using
medroxyprogesterone.
Summary: Serotonergic mediation of estrogen has important clinical implications and warrants
further evaluation.
Background
In mammalian females, estrogen that acts extracellularly
is primarily produced in the reproductive organs, and
concentrations in blood serum and other tissues change
over the lifespan and within the ovarian cycle[1]. The
most active and most studied form of estrogen in mam-
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forms are also present [2]. Changes in E2 typically occur
in conjunction with changes in progesterone, and are to
some degree dependent on progesterone priming. In this
paper, we will primarily focus on physiological levels of
E2 assuming the presence of progesterone between
puberty and menopause, and assuming its absence after
menopause. Differences in estrogen concentrations are
associated with physiological changes affecting the central
nervous system (CNS), skeletal, vascular, and immune
systems. The mechanisms producing some of these
changes have yet to be fully elucidated [3].
Estrogen receptors and serotonin receptors coexist in cells
in a wide variety of tissues, and this critical review of the
literature suggests that many of E2's effects may be medi-
ated by changes in the actions of serotonin (5HT). Serot-
onin is usually considered to be a neurotransmitter, but
surprisingly, only 1% of serotonin in the human body is
found in the CNS [4]. The remaining 99% is found in
other tissues, primarily plasma, the gastro-intestinal tract,
and immune tissues, where serotonin acts as a hormone
regulating various physiological functions including
vasodilation[5], clotting[6], recruitment of immune cells
[7-9], gastro-intestinal motility,[10] and initiation of uter-
ine contraction [11,12]. Serotonin also has peripheral
functions in a wide variety of animal phyla [13-16] and is
similar in chemical structure to auxin, which regulates
plant cell shape, growth, and movement [17].
Both naturally-occurring and pharmacologically-induced
changes in E2 alter the concentration of serotonin
through two mechanisms. First, E2 increases production
of tryptophan hydroxylase[18,19] (TPH, the rate-limiting
step in synthesis of serotonin from tryptophan), increas-
ing the concentrations of serotonin in the body [20,21].
Second, E2 inhibits the expression of the gene for the sero-
tonin reuptake transporter (SERT) and acts as an antago-
nist at the SERT, thus promoting the actions of serotonin
by increasing the time that it remains available in syn-
apses and interstitial spaces [22,23].
Beyond increasing concentrations of serotonin, E2 also
modulates the actions of serotonin because the activation
of E2 receptors affects the distribution and state of serot-
onin receptors. Higher levels of E2 in the presence of pro-
gesterone upregulate E2 β receptors (ERβ) and down
regulate E2 α receptors (ERα) [24]. ERβ activation results
in upregulation of the 5HT2A receptor,[25] while ERα acti-
vation results in an increase in 5HT1A receptors via nuclear
factor kappa B (NFkB) [26]. Therefore, increasing E2
causes an increase in the density and binding of the 5HT2A
receptor,[27,28] which could explain the observed
increases in 5HT2A density for post-menstrual teenage girls
[29]. 5HT2A activity stimulates an increase in intracellular
Ca++,[30] which causes changes in cellular function
[17,31]. 5HT2A activation subsequently causes Protein
Kinase C (PKC) activation. The effects of increased Ca++
and PKC in cells are system-specific and explain many of
the physiological consequences of serotonin activation.
One effect of PKC activation is the uncoupling of 5HT1A
auto-receptors[32] and decreasing serotonin's effect at
these receptors [33,34]. Following 5HT2A activation of
PKC, 5HT1A receptors become unable to reduce serotonin
production through negative feedback, and serotonin
concentrations increase [32-34] E2 compounds this effect
by directly inhibiting 5HT1A function [35,36].
With reduced levels of E2, 5HT1A receptors are disinhib-
ited and counter the effects of 5HT2A receptor activation.
Increased activation of 5HT1A in the immune system
results in greater mitotic potential via cyclic adenosine
monophosphate (cAMP) and extra cellular response
kinase (ERK) [37-40]. Additionally, the reinstatement of
5HT1A auto-regulation decreases serotonin concentrations
by allowing negative feedback inhibition of serotonin
production and release. Normal physiology depends on
maintaining a balance between 5HT2A receptor produced
Ca++ inflow and 5HT1A receptor suppression of cAMP pro-
duction. Pathologies result when this balance is per-
turbed, and the specific manifestation of these
pathologies depend on which system is affected.
The current literature documents a wide range of individ-
ual effects of both estrogen and serotonin, which have
been successfully used to explain both normal and patho-
logical processes. E2, for example, initiates the develop-
ment of the female reproductive system, influences the
deposition of body fat, regulates the production of prolac-
tin and other hormones, and increases sodium and water
retention [41]. Independent of estrogen, serotonin regu-
lates urination, influences the production of cerebrospi-
nal fluid, and relaxes vascular smooth muscle [42]. These
effects can be accounted for without reference to the inter-
action between E2 and serotonin. However, we hypothe-
size that considering how estrogen's actions might be
mediated by serotonin explains findings that would not
be predicted by either action alone and suggests possible
treatment strategies that have not yet been considered. It
is beyond the scope of this paper to provide an exhaustive
catalog of the individual effects of either E2 or serotonin;
we will limit our discussion to the physiological conse-
quences of E2 that are consistent with the known func-
tions of serotonin and its receptors.
Discussion
The central nervous system
Changes in estrogen are correlated with a variety of effects
in the CNS, such as changes in pain transmission, head-
ache, dizziness, nausea, temperature regulation, andPage 2 of 10
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tions[41,43] in a direction consistent with mediation of
E2 effects. For pain, E2 acts as a central analgesic,[44] and
pain sensation is inhibited by the activation of some sero-
tonergic neurons [4]. Analgesic drugs that exploit this
effect at the 5HT2A receptor are already available [4,45-
48]. We hypothesize that E2's upregulation of the 5HT2A
receptor in the brain might contribute to E2-mediated
pain relief, in which case central administration of 5HT2A
receptor antagonists would decrease E2's analgesic effects.
In the spinal cord, altered expression of 5HT2A receptors
can both increase and decrease pain [48,49]. E2's upregu-
lation of 5HT2A in the spinal cord could be a factor in the
development of fibromyalgia, which presents as increased
generalized pain sensation. Serotonergic regulation of
fibromyalgia is supported by evidence that fibromyalgia is
comorbid with other serotonin-related pathologies,[50]
and that fibromyalgia patients have altered tryptophan
metabolism[51] and can be treated with 5HT2A antago-
nists [50]. E2's effect on serotonin could also explain why
fibromyalgia is more frequently observed in females than
males [52].
Females are also at greater risk for headaches,[43] which
can result from vasodilation in the brain [53]. Activation
of an additional serotonin receptor, 5HT1B, is one mecha-
nism by which vasodilation occurs. 5HT1B receptors are
not uncoupled by E2 (unlike 5HT1A receptors), and their
vasodilatory effect is typically balanced by activation of
5HT2A receptors, which result in vasoconstriction [54].
After E2 exposure, increased serotonin concentrations
result in greater activation of both the 5HT1B and 5HT2A
receptors. Under normal conditions, upregulation and
activation of 5HT2A receptors enable them to balance the
effects of 5HT1B receptors [27,28,55]. We suggest that
females' increased headache risk might result if high sero-
tonin concentrations are maintained without adequate
compensatory 5HT2A activity.
Two of the major side effects of E2 treatment are dizziness
and nausea, which are controlled in the CNS. The mecha-
nism by which these side effects occur has not been fully
elucidated. It is possible that E2's effect on serotonin path-
ways is responsible for these symptoms, as 5HT2A recep-
tors activate vestibular neurons (which maintain
balance)[56] and are found in emetic centers, which are
involved in chemically-induced vomiting [57]. Our
hypothesis is corroborated by the use of serotonergic
drugs to minimize these side effects of E2 treatment [58].
The loss of estrogen at menopause results in decreased
density of 5HT2A receptors and lower activity of serotonin,
which could explain aberrant temperature regulation,
including hot flashes and night sweats. Although the
effects of temperature changes are felt throughout the
body, 5HT2A receptors in the CNS are responsible for tem-
perature regulation. Administration of drugs acting at the
5HT2A receptor restores normal temperature regulation
following ovariectomy[59] and chemically induced
changes in body temperature[60] The nighttime preva-
lence of hot flashes and night sweats could be a result of
the conversion of serotonin to melatonin at night, result-
ing in lower circulating serotonin levels [61]. Phytoestro-
gens preferentially bind to ERβ receptors[30] and are
effective at reducing hot flashes and night sweats [62]. The
mechanism by which these compounds work could be an
ERβ-produced upregulation of 5HT2A receptors.
Depression is more common in women than in men and
is known to be mediated by serotonin receptor levels
[43,63]. Specifically, depression is linked to decreased
density of serotonin receptors and decreased efficacy of
serotonin in the brain. The increased risk, timing of onset,
and effectiveness of treatment of depression in women
may be mediated by estrogen's effect on serotonin recep-
tors. The onset of depression in women is a characteristic
of times when estrogen levels are relatively low (in early
pregnancy, postpartum, and around and following meno-
pause) or low in comparison to progesterone (the luteal
phase of the menstrual cycle) [64,65]. In women with
depression around or following menopause, the effective-
ness of treatment with selective serotonin reuptake inhib-
itors (SSRIs) is enhanced by simultaneous administration
of estrogen,[63] and doses of estrogen alone are effective
at treating premenstrual, postpartum, and perimenopau-
sal depression, especially for depression linked to aber-
rant expression of 5HT2A receptors [25,66]. ERβ regulates
the antidepressant effect of E2 in mice; ERβ knockout
mice fail to show the decrease in immobility usually
induced by E2 doses in a forced swim test [67]. The
increased levels of serotonin and increased activity of the
5HT2A receptor caused by E2 could be the mechanism for
E2's antidepressant effects, in which case 5HT2A receptor
agonists could also enhance the anti-depressant effects of
E2.
The skeletal system
Estrogen and serotonin also affect the skeletal system. As
bones grow, they are continually remodeled and
reshaped. Normal bone development is affected by
growth hormone, parathyroid hormone, calcitonin, and
environmental factors like dietary calcium intake and
physical activity. In addition to these factors, estrogen and
serotonin play an important role in the development and
maintenance of bone mass. For bone growth to occur, two
types of cells are required: osteoblasts, which form new
bone, and osteoclasts, which resorb bone. During
puberty, osteoclasts and osteoblasts are in balance and
resorb and build bone simultaneously, but osteoporosis
results when osteoclasts increase relative to osteoblasts.Page 3 of 10
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both males and females,[68,69] and we propose that they
can be explained by examining E2-produced changes in
serotonergic function in bone growth and loss. 5HT2A
receptor activation causes an increase in expression of
osteoblast progenitor cells, maintaining bone density
[70]. SERT activation, in contrast, increases osteoclasts in
bone, aiding in bone growth in childhood,[71] but result-
ing in loss of bone density and increases in extracellular
Ca++ postpartum[72,73] and in menopause [74,75]. Stud-
ies of female mice lacking the ERα, the ERβ, or both sug-
gest these two receptors might counterbalance each
other's effects on longitudinal bone growth,[76] with ERβ
primarily responsible for decreasing bone growth and
increasing bone resorption [77]. Because ERα and ERβ
have opposing effects on serotonin systems, we hypothe-
size that mediation by serotonin could explain E2's effects
on the skeletal system: the decrease in bone density
observed following menopause or when E2 function is
otherwise compromised. However, bone loss begins
around age 30 in men and women and this early bone loss
cannot be entirely explained by differences in E2 concen-
trations or by our proposed model [78].
The vascular system
In the vascular system, estrogen and serotonin have been
shown to individually alter clotting, cholesterol, vasocon-
striction, and heart attacks. Both high and low levels of E2
have been associated with increased risk of thromboem-
bolism; high levels result in increased clot formation,
while low levels result in slower clot breakdown. Unusu-
ally high concentrations of estrogen (beyond normal
physiological levels) directly increase the likelihood of
clotting by increasing production of clotting factors VII
through X in the liver [41]. In addition, these levels of E2
might increase clotting by increasing serotonin, which is
constitutively present in human plasma and platelets and
works to promote clotting[6,79] and increase density of
platelets [58]. Increased clotting and thromboembolism
at low concentrations of E2 [80] can also be explained
using serotonergic changes. Postmenopausal women have
longer latency to lysis of clots, and E2 replacement ther-
apy returns latencies to pre-menopausal levels [81].
Patients with slower clot breakdowns have decreased
uptake and release of serotonin from platelets,[82] and at
low E2 levels serotonin's ability to break down clots via
the 5HT2A receptor is limited,[83,84] so we suggest that
lower serotonin activity associated with lower E2 levels
could also contribute to increased clotting.
Increased concentrations of E2 are also associated with
decreased cholesterol, and at menopause, there is an
increase in total serum cholesterol, which is reduced by
estrogen-containing hormone replacement therapy [85].
We suggest higher cholesterol after menopause is linked
to the effects of serotonin. Serotonin increases membrane
fluidity by incorporation of cholesterol into membranes,
decreasing bioavailable cholesterol [86,87]. Increased
membrane fluidity also increases serotonergic function,
creating a positive feedback loop [88,89]. If serotonin is
an intermediary between estrogen and cholesterol, then in
the presence of high concentrations of E2, we would
expect more cholesterol incorporated into membranes,
thereby reducing cholesterol present in the plasma. Our
hypothesis would be supported if the administration of
drugs that reduce concentrations of serotonin in the
plasma cause increases in plasma cholesterol despite con-
sistent levels of E2.
Both clotting and cholesterol contribute to heart attack
risk. Women are at lower risk of heart attack than men
prior to menopause, but changes in the vascular system
after menopause result in the loss of protection from heart
disease [41,43]. In females, recent evidence suggests that
physiological levels of E2 protect against heart attacks,
while testosterone makes heart attacks more likely [90].
E2 acting at ERβ is responsible for this protective effect, as
mice lacking ERβ have greater mortality and increased
heart failure indicators following experimentally induced
myocardial infarctions [91]. We hypothesize that these
effects in females can be explained in part by serotonin
receptor changes. Specifically, in the presence of physio-
logical E2 and therefore ERβ activation, serotonin prefer-
entially acts on 5HT2A receptors and to reduce vasospasm
in cardiac tissue. After menopause, when 5HT2A receptors
have been down regulated, serotonin instead acts on
5HT1A receptors, which cause adrenergic stimulation of
smooth muscle[92] and increase likelihood of cardiac
vasospasm [93]. This increases the risk of heart attack
[92,94-96]. In addition, testosterone, which increases fol-
lowing menopause, compounds the actions of serotonin
at 5HT1A receptors by preventing desensitization of 5HT1A
receptors [97]. These changes in sensitivity of cardiac ves-
sels, combined with increased clotting and lipid levels,
would be expected to increase heart attack risk, arterioscle-
rosis and strokes. However, E2 is not solely responsible
for protection from heart attack, progesterone also plays a
role. Hormone replacement therapy (HRT) containing E2
and medroxyprogesterone instead of E2 and progesterone
has been shown to increase heart attack [98]. Although
the study showing increased heart attack risk during HRT
is controversial,[99] it is possible that decreased concen-
trations of serotonin produced by treatment with medrox-
yprogesterone[93,100] could contribute to this increased
risk.
The immune system
Both E2 and serotonin are also active in the immune sys-
tem, and in this system, their interaction is well-docu-
mented. E2 suppresses major histocompatibility complexPage 4 of 10
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acts centrally to suppress the immune system[102] by
helping to activate 5HT2A receptors in the thymus
[28,103-105]. Estrogen treatment also indirectly sup-
presses MHC II protein expression via serotonin
[102,106]. Specifically, increased 5HT2A activity causes
decreased MHC II production,[107] and decreased selec-
tion against self-reactive helper T cells (TH1) [108]. In
addition, the concurrent inactivation of 5HT1A receptors
decreases TNF-α production [109,110]. Although self-
reactive TH1 cells are present, we hypothesize that E2's
suppression of MHC II prevents them from becoming
activated, and therefore while sufficient E2 is present they
fail to attack tissues. Following menopause, or when E2
levels are unusually low, suppression of MHC II and
immune function is lost, allowing self-reactive TH1 cells to
become active and pathogenic. It is possible that estrogen
and serotonin's modulation of the immune system pre-
vents immune attack on offspring during pregnancy
(when estrogen is at relatively high concentrations) and
avoids infection after delivery (when estrogen is relatively
low) [111].
MHC II protein and self-reactive T cells appear to be the
common denominators among autoimmune disorders in
women, suggesting a role for E2 and serotonin in mediat-
ing these disorders. Multiple sclerosis (MS) is associated
with the presence of MHC II protein polymorphic patho-
genic alleles[112,113] and serotonin depletion[114] This
serotonin depletion could be a consequence of low E2, so
the decrease in MS symptoms during pregnancy [115]
could be explained by higher concentrations of E2. Also
the severity of MS symptoms increases as serotonin levels
decrease[116], symptoms worsen in phases of the men-
strual cycle when there is low E2[117], and low levels of
E2 result in changes in the 5HT signaling pathway [118].
In female SERT knockout mice, symptoms of experimen-
tal allergic encephalomyelitis (a MS model) are less severe
and have a greater latency to occurrence, possibly as a
result of increased serotonin availability [119]. Not only
may low serotonin levels be linked to MS, but the effects
of serotonin on MS may involve 5HT2 receptors in partic-
ular. Gene-microarray analysis of brain lesions found
lower 5HT2 receptor expression in all 4 MS patients that
analysis was preformed for compared to that of 2 controls
[120].
Serotonin depletion could also be produced by conver-
sion of serotonin to melatonin in the absence of light,
which might explain the increased incidence of MS in
more northern climates[121] (where daylight periods are
shorter) and the reason that light therapy can be effective
in reducing symptoms of MS [122]. Similarly, self-
reported incidence of Type I diabetes (IDDM) is nega-
tively correlated with exposure to UV radiation and posi-
tively correlated with latitude in Australia [123].
Melatonin suppresses estrogen function [61] and sup-
presses 5HT2A receptor activity [124]. Further, melatonin
might be the link between E2 and helper T-cell (TH1)
activity, as melatonin has been shown to upregulate
expression of TH1-stimulating factors such as TNF-α and
IFN-γ [125]. TNF-α increases the expression of MHC class
II proteins and activates TH1 cells, [126] which are hall-
marks of MS.
Similar MHC class II polymorphisms and T cell dysfunc-
tions have been implicated in lupus,[127,128] and lower
levels of free tryptophan[129] and MHC II protein over
expression is also linked to autoimmune attack on beta
cells in Type I diabetes (IDDM) [130]. Over expression of
the MHC II following failure to select against self-reactive
T-cells is also a useful model for rheumatoid arthritis,
Graves disease, and Hashimoto's thyroiditis, in which T-
cells react to proteins produced in the body, failing to dis-
criminate them from invading organisms [131]. Women
in whom estrogen-regulated serotonin signaling is com-
promised would be expected to have higher levels of MHC
class II protein expression and may present these patholo-
gies. However, simply over-expressing MHC II proteins is
not sufficient to activate the immune system and induce
autoimmune disorders [131]. The links between autoim-
mune disorders, serotonergic systems, and E2 suggest that
manipulation of serotonin or E2 could be used to success-
fully treat these pathologies. Consistent with this sugges-
tion, ER agonists reduce the symptoms of autoimmune
disorders [132,133].
Breast cancer
Carcinogenesis is conceptualized as consisting of three
distinct phases: initiation, promotion and progression.
Initiation is the irreversible alteration of a normal cell;
promotion involves both proliferation of initiated cells
and suppression of apoptosis of these cells; and progres-
sion is the irreversible conversion of one of the promoted
initiated cells to an invasive, metastatic tumor cell [134].
Therefore, any endogenous milieu that induces apoptosis
or suppresses mitogenesis of initiated cells could reduce
breast cancer risk.
For breast cancer, one of the prevailing theories for the
role of E2 is that longer duration of lifetime exposure to
E2 is associated with increased risk, so that early menarche
and late menopause result in greater likelihood of devel-
oping breast cancer [135]. Adding a role for serotonin
does not conflict with this idea, but it does help explain
several epidemiological findings that are not accounted
for by a relationship between increased E2 exposure alone
and breast cancer. First, the highest breast cancer inci-
dence is in post-menopausal women, when endogenous
E2 levels are much lower than before menopause. AsPage 5 of 10
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ence of progesterone prior to menopause cause an
increase in 5HT2A receptor density and serotonin activity
that promotes apoptosis. In contrast, 5HT1A activation
(which occurs preferentially after menopause) decreases
apoptotic signaling via caspase-3 suppression [38]. There-
fore, if E2 is acting on breast cancer in part by serotonin
modulation, then we would predict that the decrease in
E2 after menopause should increase risk of breast cancer.
This is consistent with the observed breast cancer inci-
dence curve [136]. The failure of low levels of E2 to inhibit
cancer growth is also reflected in patterns of tumor devel-
opment within the estrous cycle. In mice, breast tumor
growth occurs primarily in diestrus (when E2 is low), and
tumor size is maintained or shrinks when E2 levels are
high [137].
Second, in Pike's Breast Tissue Age model, a one-time
rapid increase in breast tissue age and therefore breast can-
cer risk is included immediately following the first full-
term pregnancy [138]. The extension of Pike's model
includes multiple births by incorporating smaller
increases in risk at each additional full-term pregnancy
[139]. This pattern of increased risk for breast cancer
immediately following full-term pregnancies is well-doc-
umented [140-142]. E2 concentrations increase steadily
during pregnancy, peaking at about 100 times normal
cycling levels [3]. In the days around parturition, these
concentrations drop precipitously to levels below those of
normal cycling females, where they are maintained for at
least a month and potentially much longer (depending on
suckling suppression) [143]. We postulate that the
observed increase in breast cancer risk may be accounted
for by the concurrent decrease in E2 and therefore changes
in 5HT2A receptor function immediately prior to parturi-
tion. While E2's effect on serotonin could account for the
immediate increase in risk, it cannot explain the long-
term reduction in risk, which is likely related to other
changes associated with parturition or lactation.
Third, obesity exerts differential effects on breast cancer
risk over the lifespan; decreasing risk prior to menopause
and increasing risk following menopause [144,145].
Under the prevailing theory of cumulative E2 exposure,
obesity (which increases E2 levels[146]) would always be
expected to increase breast cancer risk. However, the effect
of E2 using serotonin mediation described above can
account for the observed differential effects. Increased E2
in the presence of progesterone increases activation of
5HT2A receptors, while increased E2 in the absence of pro-
gesterone increases activation of 5HT1A receptors. The
effects of these two receptors on apoptotic activity would
predict that obesity exerts a protective effect before meno-
pause and increases risk after menopause.
The importance of the presence of progesterone for this
protective effect is underscored by recent HRT studies,
which show that the use of estrogen and progesterone
does not increase breast cancer risk,[147] while the use of
estrogen and medroxyprogesterone (which decreases
serotonin in some tissues[14,148]) has been shown to
increase breast cancer risk. Consistent with the observed
effects of HRT, oral contraception with Depo-Provera,®
which includes medroxyprogesterone rather than proges-
terone, has been shown to increase breast cancer risk [147,
149].
Summary
Most research on pathologies in women's health has cen-
tered on changes in E2. Our review of data from a variety
of fields suggests that serotonin is one way that estrogen is
exerting its effects on physiology and pathology in
women. The primary function of E2 is reproductive, and
serotonergic mediation of the estrogen system likely pro-
vides reproductive benefits that are not yet understood.
Several of the effects we have discussed could produce
reproductive benefits: immune suppression during preg-
nancy could decrease the chance of lost pregnancies, post-
partum activation of the immune system could increase
antibodies in milk, increased clotting and vasoconstric-
tion in the uterus could prevent bleeding during birth,
and increased available calcium during lactation could
improve the quality of breast milk. Notably, the same
mechanism that results in these potential benefits in the
reproductive system also produces changes in the remain-
der of the body that have consequences for women's phys-
iology and pathologies. Whether the potential
reproductive benefit of these effects is adequate to account
for the maintenance of the estrogen/serotonin link
remains to be explored. We suggest serotonergic media-
tion might contribute to explaining E2's effects on some
pathologies, including heart attacks, multiple sclerosis,
and breast cancer. Altering specific aspects of the seroton-
ergic system, rather than simply increasing E2, could
allow clinicians to target treatments in particular tissues or
towards particular receptor types, alleviating undesirable
side effects of E2 administration. Further studies are
needed in order to unmask the precise molecular relation-
ship between estrogen and serotonin and to document
the clinical applications of this putative relationship.
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